Watch our latest videos
Explore the latest insights and developments on the way Neurizon is revolutionizing the treatment of ALS, including NUZ-001 trial updates and key milestones.
September 2025 – The Health Kick Podcast with Tim Boreham
August 2025 – Quarterly Shareholder Update Webinar, Q4 FY2025
August 2025 – NUZ-001 OLE Demonstrates Long-Term Safety and Efficacy Signals
August 2025 – Stockhead: Strong confidence remains as FDA review delayed
May 2025 – Stockhead Long Shortz: Last Patient Successfully Completes Treatment in OLE Study
May 2025 – Quarterly Shareholder Webinar Update, Q3 FY2025
July 2025 – Shareholder Update Elanco Licensing Deal
February 2025 – Fierce Biotech Webinar: Breaking New Ground in ALS Research
February 2025 – Half-Year Update: Key Developments & Future Outlook
December 2024 – Neurizon’s Mid-Year Update & Outlook: Shaping the Future of Neurodegenerative Diseases
August 2024 – Positive Interim Study Results from OLE Study in ALS
July 2024 – Investor Update: HEALEY ALS Platform Trial Selection
March 2024 – Phase 1 MEND trial results featured on Channel 7 News
Our 2025 Annual Report
